PeptideStack
5.2kquestions
20kanswers
220users

Would you accept 98.2% on a GLP-1 receptor agonist from QST without a content assay?

Asked 8 Apr 2025Modified 12 months agoViewed 11k times
7

What I am working with: 98.2% · a GLP-1 receptor agonist · QST.

I would like to set this up properly once, rather than adjust it repeatedly.

My budget is real but not tight, and my tolerance for uncertainty is low.

What would you do, and what would make you change course?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
vendor-vetting
vendor-vetting

Evaluating a supplier on evidence rather than reputation: testing history across batches, whether certificates are batch-specific, how failures…

454 questions
shareeditfollowflag
BN
askedbridget_nyathi12k158 Apr 2025

5 Answers

Accepted answer first, then by votes
99

Accepted answer

98.2 per cent purity with no content figure leaves the milligram number unmeasured. Purity says 98.2 of every 100 units of detected area is a GLP-1 receptor agonist and 1.8 is something else. Content says how many milligrams are in the glass. The two do not constrain each other: a vial can be 98.2 per cent pure and still be under label, because water and counter-ion are part of the gross mass and neither shows up as an impurity peak. If you buy one test, buy the one that changes your arithmetic.

More usefully, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Concretely, column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
KA
answered · acceptedkwn_analytical147k35820 Jun 2025
2Two of us submitted the same lot to different laboratories and got results a tenth apart. – rhian_prydderch 7 months ago
For what it is worth, my own independent result was within half a per cent of this. – hana_petrikova 5 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
38

Start from what the detector sees, because that tells you what the number means.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 27 Jul 2025 by j_wierzbicki — removed a claim I could not source

shareimprove this answerflag
JW
answeredj_wierzbicki69k1481 Jul 2025
4I would gently push back on the second point — inter-laboratory spread is wider than stated. – aine_mulcahy 10 months ago
add a comment
31

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
TM
answeredtobias_maartens171k35812 Jul 2025
5Adding a vote because this deserves more of them. – Dr_Yusuf_Adeyemi 7 months ago
4Adding for future readers: the certificate should carry the lot number, not just a batch code. – bufferline42 5 months ago
add a comment
24

Specifically, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
P9
answeredplate_count_9k78k24823 Jul 2025
18

Stated carefully, the single most important distinction is between what purity measures — the fraction of detected material that is your target — and what you actually want to know — how much of the material in the vial is your target.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
TR
answeredtobias_reint20k383 Aug 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.